PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.336
https://www.valueinhealthjournal.com/article/S1098-3015(19)32714-7/fulltext
Section Title :
Section Order :
10270
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32714-7&doi=10.1016/j.jval.2019.09.336